Placebo Power

Techniques in Vascular and Interventional Radiology

Volumn 15, Issue 2, 2012, Pages 150-152

  Knox, Katherine B ^a   Kelly, Michael E ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Endovascular procedures; Multiple sclerosis; Placebo; Sham surgery

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOVASCULAR SURGERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; MEASUREMENT; MEDICAL ETHICS; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; PLACEBO EFFECT; RISK FACTOR; SHAM PROCEDURE; SURGICAL TECHNIQUE; TREATMENT RESPONSE;

HUMANS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 84861502225     PISSN: 10892516     EISSN: 15579808     Source Type: Journal    
DOI: 10.1053/j.tvir.2012.02.008     Document Type: Article

References (42)

1. Benedetti F., Mayberg H.S., Wager T.D., et al. Neurobiological mechanisms of the placebo effect. J Neurosci 2005, 25:10390-10402.
2. Zamboni P., Galeotti R., Menegatti E., et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80:392-399.
3. Doepp F., Paul F., Valdueza J.M., et al. No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol 2010, 68:173-183.
4. Zamboni P., Galeotti R., Menegatti E., et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg 2009, 50:1348-1358.
5. de Craen A.J., Kaptchuk T.J., Tijssen J.G., et al. Placebos and placebo effects in medicine: Historical overview. J R Soc Med 1999, 92:511-515.
6. Beecher H. The powerful placebo effect. JAMA 1955, 159:1602-1606.
7. Benson H., McCallie D.P. Angina pectoris and the placebo effect. N Engl J Med 1979, 300:1424-1429.
8. Roberts A., Kewman D., Mercier L., et al. The power of nonspecific effects in healing: Implications for psychosocial and biological treatments. Clin Psychol Rev 1993, 13:375-391.
9. Benson H., Friedman R. Harnessing the power of the placebo effect and renaming it "Remembered Wellness". Annu Rev Med 1996, 47:193-199.
10. Hróbjartsson A., Gøtzsche P.C. Is the placebo powerless?. Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 2004, 256:91-100.
11. Schweinhardt P., Seminowics D., Jaeger E., et al. The anatomy of the mesolimbic reward system: A link between personality and the placebo analgesic response. J Neurosci 2009, 29:4882-4887.
12. Zubieta J.K., Stohler C.S. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci 2009, 1156:198-210.
13. Hróbjartsson A., Gøtzsche P.C. Is the placebo powerless?. An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001, 344:1594-1602.
14. Oken B.S. Placebo effects: Clinical aspects and neurobiology. Brain 2008, 131:2812-2823.
15. Craggs J.G., Price D.D., Perlstein W.M., et al. The dynamic mechanisms of placebo induced analgesia: Evidence of sustained and transient regional involvement. Pain 2008, 139:660-669.
16. Goetz C., Wuu J., McDermott M., et al. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008, 23:690-699.
17. Campbell M., Entwistle V., Cuthbertson B., et al. Developing a placebo-controlled trial in surgery: Issues of design, acceptability and feasibility. Trials 2001, 12:1-12.
18. McRae C., Cherin E., Yamazaki T.G., et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 2004, 61:412-420.
19. Cobb L.A., Thomas G.I., Dillard D.H., et al. An evaluation of internal-mammary-artery ligation by a double-blind technic. N Engl J Med 1959, 260:1115-1118.
20. Moseley J., O'Malley K., Petersen N., et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002, 347:81-88.
21. Enck P., Benedetti F., Schedlowski M. New insights into the placebo and Nocebo responses. Neuron 2008, 59:195-206.
22. Haour F. Mechanisms of the placebo effect and of conditioning. Neuroimmunomodulation 2005, 12:195-200.
23. Ader R., Cohen N. Behaviourally conditioned immunosuppression and murine systemic erythematosus. Science 1982, 215:1534-1536.
24. Goebel M.U., Trebst A.E., Steiner J., et al. Behavioral conditioning of immunosuppression is possible in humans. FASEB J 2002, 16:1869-1873.
25. Giang D., Goodman A., Schiffer R., et al. Conditioning of cyclophosphamide-induced leukopenia in humans. J Neuropsychiatry Clin Neurosci 1996, 8:194-201.
26. Buckalew L.W., Coffield K.E. An investigation of drug expectancy as a function of capsule color and size and preparation form. J Clin Psychopharmacol 1982, 2:245-248.
27. Blackwell B., Bloomfield S.S., Buncher C.R. Demonstration to medical students of placebo responses and non drug factors. Lancet 1972, 1:1279-1282.
28. Colloca L., Lopiano L., Lanotte M., et al. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet 2004, 3:679-684.
29. Bray S., Brawley L., Millen J. Relationship of proxy efficacy and reliance to home-based physical activity after cardiac rehabilitation. Rehabil Psychol 2006, 51:224-231.
30. Bensing J., Verheul W. The silent healer: The role of communication in placebo effects. Patient Educ Couns 2010, 80:293-299.
31. Dumitriu A., Popescu B. Placebo effects in neurological diseases. J Med Life3 2010, 114-121.
32. Caspi O., Bootzin R. Evaluating how placebos produce change: Logical and causal traps and understanding cognitive exploratory mechanisms. Eval Health Prof 2002, 25:436-464.
33. Klawiter E.C., Cross A.H., Naismith R.T. The present efficacy of multiple sclerosis therapeutics. Is the new 66% just the old 33%?. Neurology 2009, 73:984-990.
34. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996, 39:285-294.
35. Stankoff B., Waubant E., Confavreux C., et al. Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study. Neurology 2005, 64:1139-1143.
36. Errando C.L., Sigl J.C., Robles M., et al. Awareness with recall during general anaesthesia: A prospective observational evaluation of 4001 patients. Br J Anaesth 2008, 101:178-185.
37. Miller D.R., Blew P.G., Martineau R.J., et al. Midazolam and awareness with recall during total intravenous anaesthesia. Can J Anaesth 1996, 43:946-953.
38. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002, 96:1004-1017. American Association of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists.
39. Diener H., Dowson A., Ferrari M., et al. Unbalanced randomization influences placebo response: Scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia 1999, 19:699-700.
40. Miller F. Sham surgery: An ethical analysis. Am J Bioeth 2003, 3:41-48.
41. Polman C., Reingold S., Barkhof F., et al. Ethics of placebo-controlled clinical trials in multiple sclerosis. Neurology 2008, 70:1134-1140.
42. London A.J., Kadane J.B. Placebos that harm: Sham surgery controls in clinical trials. Stat Methods Med Res 2002, 11:413-427.